Gold prices bounce off 3-week lows; demand likely longer term
BeiGene (NASDAQ:ONC), Ltd. has officially completed its relocation from the Cayman Islands to Switzerland, now known as BeOne Medicines Ltd. This strategic move, effective May 27, 2025, was executed through a legal process known as a continuation. The company’s registration with the Commercial Register of the Canton of Basel-Stadt in Switzerland marks the formal completion of this transition.
Concurrent with the re-domiciliation, BeiGene has entered into amended agreements, including the Amended and Restated Deposit Agreement with Citibank, N.A., and related letter agreements. These documents outline the terms for holders and beneficial owners of BeiGene’s American Depositary Shares (ADSs), which remain listed on the NASDAQ Global Select Market under the ticker "ONC."
In addition to the corporate relocation, BeiGene has introduced new executive employment agreements for its key officers. These agreements, effective on the same date as the continuation, supersede previous contracts and detail the roles, compensation, and terms for the Chief Executive Officer, President and Chief Operating Officer, Chief Financial Officer, Global Head of Research and Development, and General Counsel and Corporate Secretary.
The company has also established a new indemnification agreement with its executive officers and board members. This agreement provides indemnification and advancement of expenses in connection with their service to the company.
The re-domiciliation does not affect the trading of BeiGene’s Ordinary Shares and ADSs. The Ordinary Shares will continue to trade on The Stock Exchange of Hong Kong Limited and the Science and Technology Innovation Board of the Shanghai Stock Exchange under their respective codes. The CUSIP number for the ADSs remains unchanged.
This information is based on a press release statement and reflects the company’s compliance with the Securities Exchange Act of 1934.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.